Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation
V Schachinger,
M Halle,
J Minners,
A Berg,
and
AM Zeiher
Department of Rehabilitation, Prevention and Sports Medicine, University Freiburg, Germany. schaechinger@em.uni-frankfurt.de
OBJECTIVES: We investigated the influence of lipoprotein(a) [Lp(a)] serum levels on different endothelium-dependent vasodilator stimuli representing different mechanisms of endothelium-dependent vasodilation. BACKGROUND: Lp(a) is an independent predictor for the development and progression of coronary artery disease. Impairment of endothelium-dependent vasodilation of epicardial arteries has been shown in patients with high levels of Lp(a). METHODS: In 108 patients with angiographically normal or minimally diseased coronary vessels, vasomotor responses to acetylcholine, cold pressor testing, increased blood flow and nitroglycerin were assessed. RESULTS: Lp(a) levels > or = 30 mg/dl were associated with significant dose-dependent enhancement of the vasoconstrictor response to acetylcholine [receptor-mediated vasodilation, p = 0.002; acetylcholine 10(-6) mol/liter, -29 +/- 21% vasoconstriction with Lp(a) levels > or = 30 mg/dl vs, -5.6 +/- 25% with Lp(a) levels < 30 mg/dl]. In addition, vasoconstrictor response to cold pressor test (receptor- and flow-mediated vasodilation) was significantly enhanced in patients with Lp(a) levels > or = 30 mg/dl (-13 +/- 12% vs. 1.2 +/- 16%, p = 0.005). In contrast, strictly endothelium-dependent, but non-receptor-mediated, flow-dependent dilation and endothelium-independent dilation with nitroglycerin were not compromised. Linear regression analysis revealed an inverse relation between Lp(a) and both acetylcholine-induced (r = -0.34, p = 0.0007) and cold pressor test-induced (r = -0.44, p = 0.0001) vasodilation. By multivariate analysis, Lp(a) was a strong and independent predictor of paradoxic vasoconstriction only in response to acetylcholine and cold pressor testing. Impairment of coronary blood flow increase in patients with Lp(a) levels > or = 30 mg/dl did not reach statistical significance. CONCLUSIONS: High Lp(a) levels are associated with a selective impairment of vasodilator capacity of receptor-mediated endothelial stimuli. Impaired dilator capacity of the coronary circulation associated with elevated Lp(a) levels may contribute to the pathogenesis of myocardial ischemia in response to trigger mechanisms involving receptor-mediated stimulation such as sympathetic activation.
This article has been cited by other articles:

|
 |

|
 |
 
T. Cho, Y. Jung, and M. L. Koschinsky
Apolipoprotein(a), through Its Strong Lysine-binding Site in KIV10, Mediates Increased Endothelial Cell Contraction and Permeability via a Rho/Rho Kinase/MYPT1-dependent Pathway
J. Biol. Chem.,
November 7, 2008;
283(45):
30503 - 30512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. J. Gomes and E. Buffolo
Coronary stenting and inflammation: implications for further surgical and medical treatment.
Ann. Thorac. Surg.,
May 1, 2006;
81(5):
1918 - 1925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tsimikas, H. K. Lau, K.-R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss
Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a): Short-Term and Long-Term Immunologic Responses to Oxidized Low-Density Lipoprotein
Circulation,
June 29, 2004;
109(25):
3164 - 3170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Pellegrino, E. Furmaniak-Kazmierczak, J. C. LeBlanc, T. Cho, K. Cao, S. M. Marcovina, M. B. Boffa, G. P. Cote, and M. L. Koschinsky
The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells
J. Biol. Chem.,
February 20, 2004;
279(8):
6526 - 6533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lippi, E. Arosio, M. Prior, and G. Guidi
Biochemical Risk Factors for Cardiovascular Disease in an Aged Male Population: Emerging Vascular Pathogens
Angiology,
October 1, 2001;
52(10):
681 - 687.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Schulter, P. Koolwijk, E. Peters, S. Frank, A. Hrzenjak, W. F. Graier, V. W. M. van Hinsbergh, and G. M. Kostner
Impact of Apolipoprotein(a) on In Vitro Angiogenesis
Arterioscler Thromb Vasc Biol,
March 1, 2001;
21(3):
433 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lippi and G. Guidi
Lipoprotein(a): from ancestral benefit to modern pathogen?
QJM,
February 1, 2000;
93(2):
75 - 84.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Schachinger, M. B. Britten, M. Elsner, D. H. Walter, I. Scharrer, and A. M. Zeiher
A Positive Family History of Premature Coronary Artery Disease Is Associated With Impaired Endothelium-Dependent Coronary Blood Flow Regulation
Circulation,
October 5, 1999;
100(14):
1502 - 1508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M Dart and J. P.F Chin-Dusting
Lipids and the endothelium
Cardiovasc Res,
August 1, 1999;
43(2):
308 - 322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. T. Raitakari, M. R. Adams, and D. S. Celermajer
Effect of Lp(a) on the Early Functional and Structural Changes of Atherosclerosis
Arterioscler Thromb Vasc Biol,
April 1, 1999;
19(4):
990 - 995.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. K. Koh, C. Cardillo, M. N. Bui, L. Hathaway, G. Csako, M. A. Waclawiw, J. A. Panza, and R. O. Cannon III
Vascular Effects of Estrogen and Cholesterol-Lowering Therapies in Hypercholesterolemic Postmenopausal Women
Circulation,
January 26, 1999;
99(3):
354 - 360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. O. Cannon III
Role of nitric oxide in cardiovascular disease: focus on the endothelium
Clin. Chem.,
August 1, 1998;
44(8):
1809 - 1819.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|